Questions and answers on immunization.

The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA (1995) 3.09

Update on meningococcal C conjugate vaccines. Can Commun Dis Rep (2005) 1.81

Multicenter surveillance of invasive meningococcal infections in children. Pediatrics (2006) 1.27

Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003. Can Commun Dis Rep (2006) 0.98

Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr (2003) 2.42

Invasive infections caused by haemophilus influenzae serotypes in twelve Canadian IMPACT centers, 1996-2001. Pediatr Infect Dis J (2007) 1.23

Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J (2008) 1.18

Progress in the prevention of pneumococcal infection. CMAJ (2005) 1.14

Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics (2003) 1.12

Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J (2003) 1.12

The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008. Pediatr Infect Dis J (2012) 1.04

Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine (2003) 1.01

Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J (2004) 0.95

Cortisol, behavior, and heart rate reactivity to immunization pain at 4 months corrected age in infants born very preterm. Clin J Pain (2010) 0.94

Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. Hum Vaccin (2005) 0.93

Nationwide canadian study of hepatitis a antibody prevalence among children eight to thirteen years old. Pediatr Infect Dis J (2005) 0.92

Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics (2003) 0.88

The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ (2011) 0.88

High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials (2012) 0.83

High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. J Clin Immunol (2014) 0.78

Do childhood vaccines cause thrombocytopenia? Paediatr Child Health (2009) 0.78

Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine (2011) 0.77

A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Pediatr Infect Dis J (2014) 0.77

Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine (2009) 0.77

Does vaccination with the varicella vaccine within four weeks after the measles, mumps and rubella vaccine reduce protection? Paediatr Child Health (2009) 0.76

Vaccination site reaction or bacterial cellulitis? Paediatr Child Health (2009) 0.76

Immunization delivery in British Columbia: perspectives of primary care physicians. Can Fam Physician (2014) 0.76

How long can we expect pertussis protection to last after the adolescent booster dose of tetanus-diphtheria-pertussis (Tdap) vaccines? Paediatr Child Health (2007) 0.75

Practical questions and answers about childhood immunization. Paediatr Child Health (2004) 0.75

Can children with minor illnesses be safely immunized? Paediatr Child Health (2011) 0.75

Conforming to ICMJE principles. CMAJ (2005) 0.75

Regrettable lack of definition of the "well tolerated" vaccine. Vaccine (2010) 0.75

Postvaccination thrombocytopenia in Canada. Pediatr Infect Dis J (2010) 0.75

Erythema nodosum, Mycobacterium avium lymphadenitis, and a 15-mm Mantoux test. Pediatr Infect Dis J (2007) 0.75

Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. Clin Infect Dis (2003) 0.75